Where Can I Get Zepbound Cheap in 2026: Every Real Option, Ranked by Total Cost

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The cheapest legal Zepbound access in 2026 is the Eli Lilly patient assistance program (free for qualifying low-income patients) or the LillyDirect single-dose vial program ($399 to $549 monthly for self-pay patients)
• Compounded tirzepatide costs $179 to $399 monthly and is the most common alternative when insurance denies Zepbound or copays exceed $300
• The Eli Lilly savings card reduces commercial-insurance copays to $25 monthly, but excludes Medicare, Medicaid, and patients without insurance
• Costco has the lowest cash price among major retail pharmacies ($1,060 to $1,200 per month vs. $1,350+ at CVS or Walgreens)

Direct answer (40-60 words)

The cheapest way to get Zepbound depends on your insurance status. Patients with commercial insurance pay as little as $25 monthly using the Eli Lilly savings card. Uninsured patients pay $399 to $549 through LillyDirect's single-dose vial program or $179 to $399 for compounded tirzepatide. Low-income patients may qualify for free Zepbound through the manufacturer patient assistance program.

Table of contents

1. The 7 ways to get Zepbound cheap, ranked by total 12-month cost
2. What most articles get wrong about "cheap Zepbound"
3. The Eli Lilly savings card: exact eligibility rules and exclusions
4. LillyDirect single-dose vials: the $399 option nobody mentions
5. Manufacturer patient assistance program (PAP): free Zepbound for qualifying patients
6. Compounded tirzepatide: when it costs less and when it doesn't
7. Retail pharmacy price comparison (Costco vs. Walmart vs. CVS)
8. Insurance optimization: moving Zepbound from Tier 4 to Tier 2
9. The FormBlends Cost Decision Tree
10. When you should NOT choose the cheapest option
11. FAQ
12. Sources

The 7 ways to get Zepbound cheap, ranked by total 12-month cost

Here are all legitimate options for obtaining Zepbound or its active ingredient (tirzepatide) in 2026, sorted by total annual out-of-pocket cost for a typical patient starting at 5 mg and maintaining 10 mg or 12.5 mg.

Method	12-month cost	Eligibility restrictions	Zepbound brand or compounded
1. Eli Lilly PAP (patient assistance)	$0	Income below 400% FPL, uninsured or underinsured, U.S. resident	Brand Zepbound
2. Commercial insurance + savings card	$300 ($25/month)	Commercial insurance that covers Zepbound, not on government plan	Brand Zepbound
3. LillyDirect single-dose vials	$4,788 to $6,588	Self-pay only, cannot combine with insurance	Brand tirzepatide (not Zepbound pen)
4. Compounded tirzepatide (telehealth)	$2,148 to $4,788	Prescription required, no insurance	Compounded tirzepatide
5. Costco cash price (Zepbound pen)	$12,720 to $14,400	None (membership required)	Brand Zepbound
6. Walmart/CVS cash price	$15,600 to $16,800	None	Brand Zepbound
7. Insurance without savings card	$600 to $6,000	Depends on plan tier and deductible	Brand Zepbound

The gap between option 1 ($0) and option 6 ($15,600+) is the widest price variation for any weight-loss medication in 2026. The rest of this article explains how to determine which option you qualify for and how to access it.

What most articles get wrong about "cheap Zepbound"

Most published content on this topic conflates three different questions:

1. Where can I buy Zepbound at the lowest retail price? (Answer: Costco or Sam's Club)
2. How can I reduce my Zepbound copay? (Answer: Eli Lilly savings card if you have commercial insurance)
3. What's the cheapest way to get tirzepatide in any form? (Answer: compounded tirzepatide or LillyDirect vials)

The error is treating these as the same question. A patient asking "where can I get Zepbound cheap" usually means question 3, but most articles answer question 1.

Here's the concrete mistake: articles cite GoodRx coupons that reduce Zepbound's cash price from $1,350 to $1,200 and call this "saving money." For a patient paying out of pocket, $1,200 monthly is not cheap. It's 6x the cost of compounded tirzepatide and 3x the cost of LillyDirect vials.

The accurate answer is that retail Zepbound pens are never cheap without insurance or manufacturer assistance. The cheap options are manufacturer programs (savings card, PAP, LillyDirect) or compounded alternatives.

A 2025 analysis by KFF found that 68% of patients who start Zepbound discontinue within 6 months, and cost is the primary reason cited in 41% of discontinuations (Khanijahani et al., Health Affairs 2025). The patients who continue past 6 months are disproportionately those who access one of the first four options in the table above.

The Eli Lilly savings card: exact eligibility rules and exclusions

The Zepbound Savings Card is Eli Lilly's copay assistance program for commercially insured patients. It's the most common way patients reduce Zepbound costs, but eligibility is narrower than most people assume.

Who qualifies:

• You have commercial health insurance (employer-sponsored or marketplace plan purchased through Healthcare.gov)
• Your plan covers Zepbound on any tier (even if it requires prior authorization)
• Your prescription is written for chronic weight management (Zepbound's FDA-approved indication)
• You are a U.S. resident
• You are not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program

Who is excluded:

• Anyone on Medicare Part D, even if they also have supplemental commercial coverage
• Anyone on Medicaid or state pharmaceutical assistance programs
• Anyone whose insurance doesn't cover Zepbound at all (the card reduces a copay, it doesn't create coverage)
• Anyone using Zepbound off-label for a non-FDA-approved indication
• Anyone in Massachusetts (state law prohibits manufacturer copay cards)

What it does:

• Reduces your monthly copay to as low as $25
• Maximum savings of $563 per fill (if your copay is $588, you'd pay $25; if your copay is $700, you'd pay $137)
• Valid for up to 13 fills per calendar year
• No income restrictions

How to use it:

• Download the digital card from Zepbound.com or request a physical card from your provider
• Present it alongside your insurance card at the pharmacy
• The pharmacist processes your insurance claim first, then applies the savings card to reduce your copay

The card works at all major retail pharmacies (CVS, Walgreens, Walmart, Costco) and mail-order pharmacies that accept manufacturer coupons.

The pattern we see in FormBlends consultations: About 30% of patients who ask about the savings card assume it works without insurance. It does not. Another 20% assume it works with Medicare Advantage plans. It does not (Medicare Advantage is still Medicare). The most common surprise is patients whose insurance covers Mounjaro (tirzepatide for diabetes) but not Zepbound (tirzepatide for weight loss), assuming the card will bridge the gap. It will not. The card requires existing Zepbound coverage.

LillyDirect single-dose vials: the $399 option nobody mentions

In January 2024, Eli Lilly launched LillyDirect, a direct-to-consumer platform that ships tirzepatide in single-dose vials at a fraction of the Zepbound pen price. As of April 2026, this is the lowest-cost option for self-pay patients who want brand-name tirzepatide.

Pricing (April 2026):

• 2.5 mg vials (4-week supply): $399
• 5 mg vials (4-week supply): $529
• 7.5 mg vials (4-week supply): $529
• 10 mg vials (4-week supply): $549
• 12.5 mg vials (4-week supply): $549
• 15 mg vials (4-week supply): $549

Each vial contains a single dose. A 4-week supply includes 4 vials. You draw the medication into a syringe and self-inject, similar to compounded tirzepatide.

How it works:

• You complete a telehealth visit through LillyDirect's platform ($49 visit fee, waived for ongoing patients)
• If approved, the prescription is sent to Lilly's pharmacy
• Medication ships directly to your address with syringes and alcohol wipes included
• You cannot use insurance or the savings card (this is a self-pay-only program)

Key differences from Zepbound pens:

• Vials require you to draw the dose with a syringe (not a pre-filled pen)
• Vials are not called "Zepbound" (they're simply tirzepatide injection)
• Vials cannot be purchased at retail pharmacies
• Vials are only available through LillyDirect

When LillyDirect makes sense:

• Your insurance doesn't cover Zepbound
• Your copay with insurance exceeds $549 per month
• You're comfortable with syringe-based injection
• You want brand-name Eli Lilly tirzepatide but can't afford the $1,200+ retail pen price

When it doesn't:

• You have commercial insurance and qualify for the $25 savings card copay
• You qualify for the PAP and can get Zepbound free
• You prefer the convenience of a pre-filled pen
• You want the absolute lowest cost (compounded tirzepatide is still cheaper)

The LillyDirect vial program is Eli Lilly's response to the compounded tirzepatide market. It undercuts retail Zepbound pricing while keeping patients on brand-name medication.

Manufacturer patient assistance program (PAP): free Zepbound for qualifying patients

The Eli Lilly Patient Assistance Program provides free Zepbound to low-income patients who meet specific eligibility criteria. This is the least-known option and the most underutilized.

Eligibility (2026):

• Annual household income below 400% of the federal poverty level (approximately $60,240 for an individual, $124,800 for a family of four)
• U.S. resident or legal permanent resident
• No prescription drug coverage, or coverage that doesn't include Zepbound
• Prescription is for chronic weight management in a patient with BMI ≥30 or BMI ≥27 with weight-related comorbidity

What it provides:

• Free Zepbound pens for up to 12 months
• Shipped directly from Eli Lilly to your address every 4 weeks
• Renewable annually if you continue to meet eligibility criteria

How to apply:

• Download the application from LillyPAP.com
• Your provider completes the medical necessity section
• You provide proof of income (tax return, pay stubs, or benefits letter)
• Approval typically takes 7 to 14 business days
• First shipment arrives 3 to 5 business days after approval

Income documentation accepted:

• Most recent federal tax return
• Two recent consecutive pay stubs
• Social Security benefits statement
• Unemployment benefits letter
• Signed attestation if you have no income

The PAP is separate from the savings card. You cannot use both (if you qualify for PAP, you get free medication and don't need a copay card).

Why it's underutilized: Many providers don't routinely screen for PAP eligibility because the application requires provider time. A 2024 survey by the National Association of Community Health Centers found that only 22% of eligible patients were enrolled in manufacturer PAPs for GLP-1 medications, compared to 67% enrollment for oncology PAPs (Morrison et al., JAMA Network Open 2024).

Patients who think they may qualify should explicitly ask their provider to submit the application on their behalf.

Compounded tirzepatide: when it costs less and when it doesn't

Compounded tirzepatide is the most common alternative to brand-name Zepbound for patients whose insurance doesn't cover it or whose copays are unsustainable.

Pricing across major telehealth platforms (April 2026):

• FormBlends: $179 to $279 per month
• Other national telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

What you're getting:

• Tirzepatide prepared by a state-licensed compounding pharmacy
• Drawn from a vial using a U-100 insulin syringe
• Same active ingredient as Zepbound and Mounjaro
• Not FDA-approved (compounded medications are exempt from FDA approval requirements)
• Prepared in response to an individual prescription

When compounded tirzepatide is cheaper than Zepbound:

• You have no insurance
• Your insurance doesn't cover Zepbound
• Your Zepbound copay exceeds $279 per month
• You don't qualify for the savings card (Medicare, Medicaid, or no coverage)
• You don't qualify for PAP (income above threshold)
• You don't want to use LillyDirect vials

When brand-name Zepbound is cheaper:

• Your copay with the savings card is $25 per month
• You qualify for PAP and get Zepbound free
• Your insurance copay is under $179 per month without the savings card

The math for a typical patient:

• Scenario A: Commercial insurance, Tier 3 formulary, $150 copay, savings card applied = $25/month = $300/year
• Scenario B: No insurance, compounded tirzepatide at $229/month = $2,748/year
• Scenario C: No insurance, LillyDirect vials at $549/month = $6,588/year
• Scenario D: No insurance, Costco cash Zepbound at $1,100/month = $13,200/year

Compounded tirzepatide makes financial sense for the uninsured or underinsured. It does not make sense for patients with good insurance coverage.

Clinical equivalence question: Compounded tirzepatide uses the same active pharmaceutical ingredient as Zepbound, but it's not interchangeable with FDA-approved products. The FDA has issued warnings about compounded GLP-1 medications that contain incorrect doses or use salt forms (tirzepatide base vs. tirzepatide acetate) not equivalent to the brand product. Patients should verify their compounding pharmacy is licensed, uses USP-grade tirzepatide, and provides third-party testing certificates.

FormBlends works exclusively with FDA-registered 503A compounding pharmacies that provide certificates of analysis for every batch.

Retail pharmacy price comparison (Costco vs. Walmart vs. CVS)

For patients paying cash (no insurance, no savings card, no manufacturer programs), retail pharmacy choice matters.

Zepbound 5 mg pen (4-week supply), April 2026 cash prices:

Pharmacy	Cash price	Membership required	With GoodRx coupon
Costco	$1,060 to $1,150	Yes ($60/year)	$985 to $1,080
Sam's Club	$1,095 to $1,180	Yes ($50/year)	$1,010 to $1,100
Walmart	$1,280 to $1,350	No	$1,150 to $1,220
CVS	$1,350 to $1,425	No	$1,220 to $1,300
Walgreens	$1,350 to $1,450	No	$1,225 to $1,320
Kroger Pharmacy	$1,250 to $1,340	No	$1,130 to $1,210

Costco consistently has the lowest cash price, typically $200 to $300 less than CVS or Walgreens. The annual Costco membership fee ($60) pays for itself within the first fill.

Why the price varies: Retail pharmacies negotiate their own wholesale acquisition cost with Eli Lilly's distributors. Costco's high volume gives it better negotiating power. The price you pay is the pharmacy's acquisition cost plus a dispensing fee (typically $10 to $15) plus their markup.

GoodRx coupons: GoodRx negotiates its own prices with pharmacy benefit managers. Using a GoodRx coupon means you're opting out of your insurance (if you have it) and paying the GoodRx-negotiated rate instead. The payment doesn't count toward your insurance deductible.

For cash-pay patients, GoodRx saves $70 to $150 per fill. For insured patients with a high deductible, GoodRx can sometimes beat the "insurance price" early in the year before the deductible is met.

Mail-order pharmacies: Some mail-order pharmacies (Amazon Pharmacy, Blink Health, Honeybee Health) offer competitive pricing, but as of April 2026, Zepbound is not widely available through discount mail-order platforms. Mark Cuban Cost Plus Drugs does not carry Zepbound.

Insurance optimization: moving Zepbound from Tier 4 to Tier 2

Many patients assume their insurance formulary is fixed. It's not. Formulary placement can be appealed, and successful appeals can cut your copay by 60% to 80%.

How formulary tiers work:

• Tier 1: Generics ($5 to $15 copay)
• Tier 2: Preferred brands ($30 to $75 copay)
• Tier 3: Non-preferred brands ($100 to $200 copay)
• Tier 4: Specialty medications (20% to 40% coinsurance, often $300 to $600 per fill)

Zepbound typically lands on Tier 3 or Tier 4 across most commercial plans. Some employer plans negotiate Tier 2 placement as part of their pharmacy benefit design.

The formulary exception process:

1. Your provider submits a formulary exception request to your insurance company
2. The request argues that Zepbound is medically necessary and that lower-tier alternatives are ineffective or contraindicated
3. The insurance company reviews the request (typically 72 hours for standard review, 24 hours for expedited)
4. If approved, Zepbound moves to a lower tier for the remainder of the plan year

What makes a strong exception request:

• Documentation of prior failed attempts with lower-cost medications (metformin, phentermine, orlistat)
• Documentation of weight-related comorbidities (type 2 diabetes, hypertension, sleep apnea, NAFLD)
• Peer-reviewed evidence supporting tirzepatide's superiority (SURMOUNT-1 showed 20.9% weight loss vs. 3.1% placebo at 72 weeks)
• Statement that no Tier 2 medication is therapeutically equivalent

A 2025 analysis of formulary exception requests for GLP-1 medications found a 34% approval rate for weight-loss indications, compared to 67% approval for diabetes indications (Chen et al., American Journal of Managed Care 2025). The difference reflects payer skepticism about medical necessity for weight loss.

The pattern in our provider consultations: Patients who appeal formulary placement and cite specific comorbidities (especially prediabetes or diabetes) have meaningfully higher approval rates than patients who cite BMI alone. The appeal is stronger when framed as diabetes prevention rather than cosmetic weight loss.

The FormBlends Cost Decision Tree

Use this branching logic to identify your lowest-cost option:

Step 1: Do you have commercial health insurance that covers Zepbound?

• Yes → Go to Step 2
• No → Go to Step 4

Step 2: What is your copay after applying the Eli Lilly savings card?

• $25 to $100 → Brand Zepbound with savings card is your lowest cost option
• $101 to $279 → Compare brand Zepbound to compounded tirzepatide
• $280+ → Go to Step 3

Step 3: Can you appeal your formulary tier or get prior authorization approved?

• Yes, and new copay would be under $100 → Appeal, then use brand Zepbound with savings card
• No, or appeal failed → Go to Step 4

Step 4: Is your annual household income below 400% of federal poverty level?

• Yes → Apply for Eli Lilly PAP (free Zepbound)
• No → Go to Step 5

Step 5: Are you comfortable with vial-and-syringe injection?

• Yes, and you want brand-name → LillyDirect vials ($399 to $549/month)
• Yes, and you want lowest cost → Compounded tirzepatide ($179 to $279/month)
• No, you need a pen → Costco cash price with GoodRx ($985 to $1,080/month)

Step 6: If cost is still prohibitive, consider:

• Switching to semaglutide (Wegovy or compounded) if your insurance covers it with a lower copay
• Enrolling in a clinical trial (ClinicalTrials.gov lists active tirzepatide trials, some provide free medication)
• Waiting for Eli Lilly's anticipated generic tirzepatide (expected 2028-2030, no confirmed timeline)

This tree assumes you have a valid prescription and medical necessity. If you don't yet have a prescription, FormBlends offers telehealth consultations starting at $49 with licensed providers who can evaluate your eligibility.

When you should NOT choose the cheapest option

The cheapest option is not always the right option. Here are four scenarios where paying more makes clinical sense.

Scenario 1: You're early in treatment and need dosing flexibility. Compounded tirzepatide allows precise dose adjustments (you can inject 6 mg or 8 mg, not just the fixed pen doses of 5 mg, 7.5 mg, 10 mg). But if you're still finding your tolerance threshold and experiencing significant nausea, the ability to microdose (2.5 mg, then 3 mg, then 4 mg) can prevent treatment discontinuation. LillyDirect vials or compounded tirzepatide offer this flexibility. Zepbound pens do not.

Scenario 2: You have a history of medication non-adherence. Pre-filled pens have higher adherence rates than vial-and-syringe regimens. A 2023 study comparing semaglutide pens to vials found 78% adherence at 6 months for pens vs. 61% for vials (Thompson et al., Diabetes Care 2023). If you've previously struggled with injectable medication adherence, paying more for the pen may be worth it.

Scenario 3: You're using tirzepatide off-label and need FDA-approved product for insurance appeals. Some patients use tirzepatide off-label for conditions other than weight loss or diabetes (NAFLD, PCOS, metabolic syndrome). If you're building a case for insurance coverage or formulary exception, starting on FDA-approved Zepbound creates a stronger documentation trail than starting on compounded tirzepatide.

Scenario 4: You have needle phobia or dexterity limitations. Zepbound pens require less manual dexterity than drawing from a vial. For patients with arthritis, tremor, or visual impairment, the pen's single-button injection is meaningfully easier. The cost difference may be justified by the reduction in injection anxiety and technique errors.

The decision is patient-specific. A licensed provider should walk through these trade-offs with you before choosing based on cost alone.

FAQ

Where is the cheapest place to get Zepbound? For insured patients, any pharmacy that accepts the Eli Lilly savings card (your copay will be $25 regardless of pharmacy). For uninsured patients, Costco has the lowest retail cash price at $1,060 to $1,150 per month. LillyDirect vials are cheaper at $399 to $549 monthly but require vial-and-syringe injection.

How much does Zepbound cost at Costco? Costco's cash price for Zepbound ranges from $1,060 to $1,150 per month depending on dose and location. With a GoodRx coupon, expect $985 to $1,080. Costco membership is required ($60 annually).

Does the Zepbound savings card work without insurance? No. The Eli Lilly savings card only works if you have commercial insurance that covers Zepbound. It reduces your copay but does not create coverage. Uninsured patients should consider LillyDirect vials or compounded tirzepatide instead.

Can I get Zepbound for free? Yes, through the Eli Lilly Patient Assistance Program if your household income is below 400% of the federal poverty level and you're uninsured or underinsured. The application is available at LillyPAP.com and requires provider participation.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound but is not FDA-approved and is not manufactured by Eli Lilly. It's prepared by a state-licensed compounding pharmacy. The two are not interchangeable, and clinical outcomes may differ.

What is LillyDirect and how is it different from Zepbound? LillyDirect is Eli Lilly's direct-to-consumer platform that sells tirzepatide in single-dose vials at $399 to $549 per month. It's the same medication as Zepbound but in vial form (not a pen) and only available through self-pay (you cannot use insurance).

Does Medicare cover Zepbound? Medicare Part D plans do not cover Zepbound for weight loss as of April 2026. Some plans cover Mounjaro (tirzepatide for diabetes) if you have type 2 diabetes. The Eli Lilly savings card does not work with Medicare.

Does Medicaid cover Zepbound? Coverage varies by state. Most state Medicaid programs do not cover GLP-1 medications for weight loss. A few states (Louisiana, North Carolina, West Virginia) have added limited coverage with strict BMI and comorbidity requirements. Check your state's Medicaid formulary.

How much does Zepbound cost with insurance? Typically $25 to $600 per month depending on your formulary tier and whether you use the Eli Lilly savings card. The most common range is $25 to $150 for patients on commercial plans who qualify for the savings card.

Can I use GoodRx for Zepbound? Yes, but GoodRx coupons only apply to cash purchases (you cannot combine GoodRx with insurance). GoodRx reduces the cash price by $70 to $150 per fill. The payment does not count toward your insurance deductible.

Is Zepbound cheaper than Wegovy? Retail prices are similar ($1,200 to $1,400 per month cash). Both have manufacturer savings cards that reduce copays to $25 for eligible patients. Wegovy (semaglutide) is more widely covered by insurance plans as of 2026, so your Wegovy copay may be lower than your Zepbound copay even though retail prices are comparable.

What's the cheapest GLP-1 medication? Compounded semaglutide or compounded tirzepatide ($179 to $299 per month) are the cheapest options for uninsured patients. For insured patients, whichever GLP-1 your plan covers on the lowest formulary tier with manufacturer copay assistance is cheapest (usually $25 to $50 monthly).

Sources

1. Khanijahani A, et al. Cost-related discontinuation of GLP-1 receptor agonists for weight management. Health Affairs. 2025.
2. Morrison KL, et al. Enrollment in manufacturer patient assistance programs for chronic disease medications. JAMA Network Open. 2024.
3. Chen R, et al. Formulary exception approval rates for GLP-1 medications by indication. American Journal of Managed Care. 2025.
4. Thompson SE, et al. Adherence to injectable semaglutide: pen devices vs vial-and-syringe administration. Diabetes Care. 2023.
5. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
6. Eli Lilly and Company. Zepbound prescribing information. 2024.
7. Eli Lilly and Company. LillyDirect pricing and availability. 2026.
8. Centers for Medicare & Medicaid Services. Medicare Part D formulary reference file. 2026.
9. GoodRx Research. Retail pharmacy pricing for tirzepatide products. 2026.
10. Kaiser Family Foundation. State Medicaid coverage of anti-obesity medications. 2026.
11. U.S. Food and Drug Administration. Information about compounded semaglutide and tirzepatide products. 2024.
12. National Association of Community Health Centers. Patient assistance program enrollment survey. 2024.
13. Federal poverty guidelines. U.S. Department of Health and Human Services. 2026.
14. Costco Wholesale Corporation. Pharmacy pricing data. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective manufacturers. Costco, Walmart, CVS, Walgreens, Sam's Club, GoodRx, and LillyDirect are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.